GLP-1 Receptor Agonists: What It Depletes and How to Replenish

GLP-1 agonists cause rapid weight loss, but 25–40% of weight lost is lean muscle mass — not fat. This accelerates sarcopenia (age-related muscle loss), which is already the primary driver of frailty and mortality in aging. Inadequate protein intake during GLP-1 therapy dramatically worsens this.

Wilding et al. NEJM (2021) — SUSTAIN-6 and STEP trials confirmed significant lean mass loss; Biolo et al. — inadequate protein intake worsens GLP-1 induced muscle loss

Weakness, reduced strength metrics, fatigue, loss of functional capacity, worsened body composition despite weight loss

GLP-1 agonists markedly slow gastric emptying and reduce appetite, leading to reduced food intake. Vitamin B12 requires intrinsic factor secreted by gastric parietal cells and adequate stomach acid — both of which are compromised by reduced food intake and altered GI motility.

Emerging evidence — nutritional deficiency is a documented class concern; FDA labeling notes GI side effects relevant to nutrient absorption

Fatigue, neuropathy, cognitive impairment, macrocytic anemia (often slow to develop)

Severely reduced caloric intake from GLP-1-induced appetite suppression leads to inadequate micronutrient intake across the board. Vitamin D and calcium deficiency worsen the muscle and bone loss caused by lean mass reduction.

Standard nutritional consequence of very-low-calorie states — confirmed in bariatric surgery analogy literature (comparable GI alterations)

Bone density loss, compounding muscle weakness, immune impairment